Dr Reddy’s Rituximab biosimilar Ituxredi gets EMA CHMP positive recommendation

Dr Reddy’s Laboratories announced that the EMA’s committee recommended its Rituximab biosimilar Ituxredi for the European market. The decision will be reviewed by the European Commission for final approval. A separate application will be made to the UK MHRA. Earlier, the company received the EU GMP certificate for its manufacturing facility in Hyderabad.